Sandoz Group (OTCMKTS:SDZNY) Sees Large Volume Increase - What's Next?

Key Points

• Sandoz Group AG experienced a notable trading volume increase with approximately 26,312 shares traded, although this represents a 17% decline from the previous session's volume.
• Jefferies Financial Group has downgraded Sandoz Group's rating from "strong-buy" to "hold", reflecting a changing sentiment among analysts.
• The stock is currently trading at $60.20, showing an increase of 1.8% from its previous close of $59.43.

Sandoz Group AG Sponsored ADR (OTCMKTS:SDZNY - Get Free Report) saw unusually-high trading volume on Wednesday . Approximately 26,312 shares traded hands during trading, a decline of 17% from the previous session's volume of 31,770 shares.The stock last traded at $60.20 and had previously closed at $59.43.

Wall Street Analysts Forecast Growth

Separately, Jefferies Financial Group downgraded Sandoz Group from a "strong-buy" rating to a "hold" rating in a report on Friday, August 8th. Three analysts have rated the stock with a Hold rating, According to data from MarketBeat, the company has an average rating of "Hold".

Sandoz Group Trading Up 1.8%

The company has a current ratio of 1.29, a quick ratio of 0.82 and a debt-to-equity ratio of 0.62. The firm has a 50-day simple moving average of $59.89 and a 200-day simple moving average of $52.38.

About Sandoz Group

Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, diabetes, immunology, endocrinology, hematology, and ophthalmology, as well as bone disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.